Making the Invisible, Visible
![Making the Invisible, Visible](/sites/default/files/2023-05/Making-the-Invisible-Visible.jpeg)
What constitutes meaningful quality of life from the perspective of a patient with advanced IPF?
Every patient will have a different idea of what it means for them to live a quality life with idiopathic pulmonary fibrosis (IPF). This video explores how clinicians and patients differ about what they think constitutes a meaningful quality of life (QoL). Understanding these gaps could help you to consider what management techniques can support your patient's quality of life.
Related Content
![Pie chart with random percentage values in the article teaser.](/sites/default/files/2021-07/01-elements-placeholder-card-16-9_3.png)
Critical threat of fibrotic ILDs
Pulmonary fibrosis is a critical threat across a broad range of ILDs.2–5
![Card presenting 5-year mortality rates of non-IPF ILDs.](/sites/default/files/2021-07/01-elements-placeholder-card-16-9_10.png)
Increased mortality rates
Pulmonary fibrosis is a key driver of early mortality in patients with fibrotic ILDs.5–8
![Picture of three ILD patients (2 male and female).](/sites/default/files/2021-07/01-elements-placeholder-card-16-9_9.png)
ILD patient cases for evaluation and diagnosis
Download our patient cases: medical histories of representative patients.
Resources for patients
![Two seniors smiling together.](/sites/default/files/2021-07/image.png)
![Life with Pulmonary Fibrosis website logo.](/sites/default/files/2021-07/logo-primary_0.png)
Helping patients and their loved ones to learn more about their condition.
![Scleroderma female patient looking into the window.](/sites/default/files/2021-07/image_0.png)
![More then scleroderma website logo.](/sites/default/files/2021-07/logo-primary_1.png)
Providing information and resources to help support and guide patients.
- Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: A double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4(1):e000212
- Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013;10(4):362-370.
- Caban JJ, Yao J, Bagci U, Mollura DJ. Monitoring pulmonary fibrosis by fusing clinical, physiological, and computed tomography features. Conf Proc IEEE Eng Med Biol Soc. 2011;6216-6219.
- Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, on behalf of the IPF Consensus Working Group. Eur Resp J. 2018;51:1800692.
- Fischer A and Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin Rheumatol. 2019;38(10):2673–2681.
- Mathai SC and Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819.
- Wallace B, Vummidi D, Khanna D. Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Curr Opin Rheumatol. 2016;28(3):236–245.
- Spagnolo P, Cordier JF, Cottin V. Connective tissue diseases, multimorbidity and the ageing lung. Eur Respir J. 2016;47(5):1535–1558.